Agilent to Acquire Biocare Medical in $950M Pathology Diagnostics Deal

Santa Clara, CA & San Francisco, CA, March 9, 2026 (Business Wire) -- Agilent Technologies announced it has agreed to acquire Biocare Medical for $950 million in cash, expanding its portfolio in clinical and research pathology solutions. Biocare develops antibodies, reagents, and instruments used in technologies such as immunohistochemistry (IHC), in situ hybridization (ISH), and fluorescence in situ hybridization (FISH), and generated over $90 million in revenue in 2025 while maintaining double-digit annual growth since 2021. Agilent expects the acquisition to strengthen its cancer diagnostics capabilities, improve its recurring non-instrument revenue mix, and contribute positively to revenue growth and margins within the first year after closing.

Read full article here.